SCHEMBL204515

SCHEMBL204515

O=C(O)c1ccc2c(c1)sc1cc(C(=O)O)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
HKDC1 Q2TB90 1/20 0.48
TSHR P16473 2/20 0.48
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
LMNA P02545 1/20 0.47
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA4 P22748 3/20 0.46
CA6 P23280 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30414903 1.00 KDM4E (0.48) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL30414825 0.96 KDM4E (0.46) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL29762008 0.90 CYP1A2 (0.54) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL11249253 0.90 CYP1A2 (0.54) KDM4ENPC1RAB9AL3MBTL1TDP1
Hydrochloric Acid SCHEMBL11595018 0.90 CYP1A2 (0.50) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL28456554 0.90 TTR (0.49) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL11244432 0.89 CYP1A2 (0.53) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL11253003 0.87 BCKDK (0.58) NPC1RAB9ATSHRTBXAS1BCKDK
SCHEMBL2486863 0.87 KDM4E (0.46) KDM4ENPC1RAB9AL3MBTL1TDP1
SCHEMBL11240719 0.84 BCL2L1 (0.49) KDM4ENPC1RAB9AL3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117510814-B Liquid crystal polymer, fiber, preparation method of liquid crystal polymer and fiber, and conductive fiber 宁波聚嘉新材料科技有限公司 2024-03-29 CN claimed
CN-117510814-A Liquid crystal polymer, fiber, preparation method of liquid crystal polymer and fiber, and conductive fiber 宁波聚嘉新材料科技有限公司 2024-02-06 CN claimed
US-8968711-B2 Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process L'OREAL (FR) 2015-03-03 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
CN-117510814-B Liquid crystal polymer, fiber, preparation method of liquid crystal polymer and fiber, and conductive fiber 宁波聚嘉新材料科技有限公司 2024-03-29 CN disclosed
CN-117510814-B Liquid crystal polymer, fiber, preparation method of liquid crystal polymer and fiber, and conductive fiber 宁波聚嘉新材料科技有限公司 2024-03-29 CN disclosed
CN-117510814-A Liquid crystal polymer, fiber, preparation method of liquid crystal polymer and fiber, and conductive fiber 宁波聚嘉新材料科技有限公司 2024-02-06 CN disclosed
CN-117510814-A Liquid crystal polymer, fiber, preparation method of liquid crystal polymer and fiber, and conductive fiber 宁波聚嘉新材料科技有限公司 2024-02-06 CN disclosed
EP-4204100-A1 HAIR LIGHTENING COMPOSITIONS PROVIDING DAMAGE PROTECTION AND SENSORIAL BENEFITS AND METHODS OF USE L'OREAL (FR) 2023-07-05 EP disclosed
CN-116322616-A Hair lightening compositions providing damage protection and sensory benefits and methods of use 欧莱雅 2023-06-23 CN disclosed
CN-116041363-A Benzothiophene sulfone organic crystal, preparation and application as photocatalyst 华中科技大学 2023-05-02 CN disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US disclosed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US disclosed
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION L'OREAL (FR) 2009-01-29 US disclosed
WO-2001019792-A1 COVALENTLY LINKED DIMERIC DNA BINDING MOLECULES GENELABS TECHNOLOGIES, INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 KDM4E 2504/4885NPC1 4765/4885RAB9A 4090/4885
US-20090028807-A1 COMPOSITION COMPRISING A POLYCONDENSATE, METHOD OF TREATMENT, POLYCONDENSATE, AND METHOD OF PREPARATION CUTA, SYMPK, TPRKB KDM4E 1615/4885NPC1 3829/4885RAB9A 4503/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA KDM4E 1109/4885NPC1 3993/4885RAB9A 4824/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 KDM4E 2496/4885NPC1 516/4885RAB9A 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.